Merck’s Keytruda faces 2028 biosimilar rights warning
Merck priced at $151.07 received a warning as Cipla’s U.S. subsidiary secured exclusive U.S. commercialization rights for Qilu Pharmaceutical’s proposed pembrolizumab biosimilar QL21.
Merck NYSE:MRK, the pharmaceutical and vaccine heavyweight, was priced at $151.07 on Thursday as the market focused on a sharper warning over Keytruda’s biosimilar outlook. Cipla's U.S. subsidiary has secured exclusive American commercialization rights to Qilu Pharmaceutical's proposed pembrolizumab biosimilar, QL21.